D

    Denali Therapeutics Inc (DNLI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.76
    -0.24 (-1.00%)

    Market Cap: $3.80B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(19/35)
    Avg Surprise
    +15.00%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.42
    Range$-0.88 - $0.37
    17 analysts
    EPS Revisions
    3
    0
    7d
    3
    1
    30d
    EPS Estimate Drift
    90d ago$-0.53-26.9%
    60d ago$-0.53-27.2%
    30d ago$-0.64-53.4%
    7d ago$-0.41+3.4%
    Current$-0.42
    Revenue Consensus
    $23M
    Range$8M - $205M
    18 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.75
    Range$-1.16 - $0.16
    16 analysts
    Revenue Consensus
    $23M
    Range$-5601340 - $235M
    19 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.75---
    Sep 26EST
    		-$-0.42---
    Jun 26
    Reported Aug 6
    		$-0.68$-0.72+5.56%Beat+5.6%
    Mar 26
    Reported May 7
    		$-0.69$-0.71+2.82%Beat+11.5%
    Dec 25
    Reported Feb 26
    		$-0.73$-0.75+2.67%Beat-9.0%
    Sep 25
    Reported Nov 6
    		$-0.74$-0.76+2.63%Beat-17.5%
    Jun 25
    Reported Aug 11
    		$-0.72$-0.74+2.70%Beat-22.0%
    Mar 25
    Reported May 6
    		$-0.78$-0.70-11.43%Miss+0.0%
    Dec 24
    Reported Feb 27
    		$-0.67$-0.85+20.79%Beat+22.1%
    Sep 24
    Reported Nov 6
    		$-0.63$-0.63+0.00%Beat+12.5%
    Jun 24
    Reported Aug 1
    		$-0.59$-0.69+14.49%Beat-145.4%
    Mar 24
    Reported May 7
    		$-0.78$-0.66-18.18%Miss+2.5%
    Dec 23
    Reported Feb 27
    		$-0.86$-0.80-7.50%Miss-14.7%
    Sep 23
    Reported Nov 7
    		$-0.72$-0.79+8.86%Beat+14.3%
    Jun 23
    Reported Aug 8
    		$1.30$-0.63+306.35%Beat+370.8%
    Mar 23
    Reported May 8
    		$-0.80$-0.70-14.29%Miss-50.9%
    Dec 22
    Reported Feb 27
    		$-0.75$-0.79+5.06%Beat-21.0%
    Sep 22
    Reported Nov 3
    		$-0.84$-0.79-6.33%Miss-21.7%
    Jun 22
    Reported Aug 8
    		$-0.48$-0.55+12.73%Beat+4.0%
    Mar 22
    Reported May 5
    		$-0.53$-0.45-17.78%Miss+8.6%
    Dec 21
    Reported Feb 28
    		$-0.62$-0.41-51.22%Miss-132.5%
    Sep 21
    Reported Nov 4
    		$-0.69$-0.38-81.58%Miss-27.8%
    Jun 21
    Reported Aug 4
    		$-0.50$-0.36-38.89%Miss+10.7%
    Mar 21
    Reported May 3
    		$-0.58$-0.34-70.59%Miss-5.5%
    Dec 20
    Reported Feb 25
    		$1.91$-0.60+418.33%Beat+441.1%
    Sep 20
    Reported Nov 5
    		$-0.54N/A-124.55%Miss-12.5%
    Jun 20
    Reported Aug 7
    		$-0.56$-0.61+8.20%Beat+8.2%
    Mar 20
    Reported May 7
    		$-0.55$-0.57+3.51%Beat-34.1%
    Dec 19
    Reported Feb 27
    		$-0.56$-0.58+3.45%Beat-170.9%
    Sep 19
    Reported Nov 6
    		$-0.48$-0.55+12.73%Beat-26.3%
    Jun 19
    Reported Aug 6
    		$-0.61$-0.46-32.61%Miss-3.4%
    Mar 19
    Reported May 8
    		$-0.41$-0.44+6.82%Beat-57.7%
    Dec 18
    Reported Mar 12
    		$0.79$-0.11+818.18%Beat+206.8%
    Sep 18
    Reported Nov 8
    		$-0.38$-0.29-31.03%Miss+28.3%
    Jun 18
    Reported Aug 9
    		$-0.59$-0.22-168.18%Miss+75.0%
    Mar 18
    Reported May 11
    		$-0.26$0.30-186.67%Miss-
    Dec 17
    Reported Mar 19
    		$-0.74$-0.20-270.00%Miss-
    Sep 17
    Reported Dec 8
    		$-0.53$0.00N/AMiss-
    Mar 17
    Reported May 4
    		$-2.36$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.37EV/EBITDA86.48x
    Price/FCF-10.11xFCF Yield-9.89%
    Profitability
    Profit Margin0.00%Operating Margin-3601.00%
    ROE-54.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.37xQuick Ratio8.32x
    Trading Statistics
    Beta1.00Avg Volume1.21M
    52-Week High$27.3052-Week Low$12.58

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.60
    SMA 20$24.63
    SMA 50$24.57
    SMA 200$20.73
    EMA 10$24.42
    EMA 20$24.44
    EMA 50$23.92
    EMA 200$21.06

    MACD

    Line: 0.06Signal: 0.18Hist: -0.13

    ADX

    ADX: 14.8+DI: 16.3-DI: 26.7

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down20.0
    PSAR$25.52

    Bollinger Bands

    Upper Band$25.54
    Lower Band$23.73
    %B Position733%(Upper)
    Band Width0.02

    RSI (14-Day)

    Neutral
    45.0

    Momentum Oscillators

    Stoch %K32.0
    Stoch %D44.1
    Williams %R-84.7
    ROC (10d)-2.4%
    Momentum-0.59
    CCI (20d)-167.2
    MFI (14d)36.0

    Volatility Measures

    ATR (14d)$0.93(3.9%)
    StdDev (20d)0.45
    Hist Vol37.1%(Moderate)

    Volume Flow

    VWAP$23.72
    OBV21.0M
    AD Line-10.6M
    CMF (20d)0.094

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.8x
    VWMA (20d)$24.67

    Pivot Points

    R3$25.13
    R2$24.87
    R1$24.44
    Pivot Point$24.18
    S1$23.74
    S2$23.48
    S3$23.05

    Advanced Oscillators

    TSI1.75
    Ultimate Osc50.8
    KST10.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.60M$0$0$0$0$0$0$0$0$0$-305,043,000$1.27M
    Cost of Revenue$93,000$0$2.87M$0$0$0N/A$0$0$0$2.18M$0
    Gross Profit$3.51M$0$-2,866,000$0$0$0N/A$0$0$0$-307,220,000$1.27M
    Operating Expenses$134.05M$137.36M$137.37M$137.43M$134.96M$145.58M$129.85M$123.19M$116.59M$117.72M$132.57M$115.06M
    R&D$97.02M$103.85M$97.91M$101.95M$102.70M$116.23M$99.79M$98.24M$91.40M$107.02M$107.80M$89.74M
    SG&A$36.28M$33.51M$39.46M$35.48M$32.27M$29.35M$30.06M$24.95M$25.19M$25.24M$24.77M$25.32M
    Operating Income$-130,541,000$-137,357,000$-137,365,000$-137,434,000$-134,963,000$-145,580,000$-129,846,000$-123,187,000$-116,593,000$-117,715,000$-132,572,000$-113,795,000
    Interest Income$2.99M$8.91M$8.92M$10.53M$10.84M$12.61M$15.16M$15.99M$17.57M$15.91M$13.13M$14.44M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-127,553,000$-128,447,000$-128,447,000$-126,902,000$-124,119,000$-132,970,000$-114,685,000$-107,192,000$-99,026,000$-101,802,000$-119,443,000$-99,353,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-127,553,000$-128,447,000$-128,549,000$-126,902,000$-124,119,000$-132,970,000$-114,753,000$-107,192,000$-99,026,000$-101,802,000$-119,473,000$-99,353,000
    EBITDA$-126,057,000$-133,596,000$-133,583,000$-133,572,000$-131,007,000$-142,368,000$-127,227,000$-120,918,000$-114,651,000$-115,553,000$-130,395,000$-92,192,000
    EBIT$-130,541,000$-137,357,000$-137,365,000$-137,434,000$-134,963,000$-145,580,000$-129,846,000$-123,187,000$-116,593,000$-117,715,000$-132,572,000$-113,795,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DNLI

    News

    Understanding the Setup: (DNLI) and Scalable Risk

    This article provides an analysis of Denali Therapeutics Inc. (NASDAQ: DNLI) based on AI-generated signals and institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with specific entry and exit points, targets, and stop losses for various risk profiles. The analysis also details support and resistance levels across different time horizons.

    Stock Traders Daily•8/31/26•
    Neutral

    B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

    B. Riley has increased its price target for Denali Therapeutics to $35 from $30, while reiterating a "Buy" rating for the biopharmaceutical company. The adjustment reflects B. Riley's continued positive outlook on Denali Therapeutics, which specializes in developing biotherapeutics for neurological diseases. Other financial institutions like UBS and Wedbush have also recently adjusted their price targets for Denali Therapeutics, generally maintaining positive ratings.

    marketscreener.com•8/25/26•
    Bullish

    145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC

    Great Lakes Advisors LLC has purchased a new stake of 145,045 shares in Denali Therapeutics Inc. (NASDAQ:DNLI) valued at approximately $3,731,000 during the second quarter. Other institutional investors have also adjusted their holdings in Denali Therapeutics, and the company's stock has a "Moderate Buy" consensus rating from analysts with a target price of $35.92. Denali Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.

    MarketBeat•8/21/26•
    Bullish

    Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI

    Bank of America Corp DE increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 21.7% in the first quarter, now holding 1.13 million shares valued at approximately $21.8 million. Institutional investors collectively own 92.92% of DNLI, and analysts maintain a "Moderate Buy" rating with an average target price of $35.92. Despite missing EPS estimates, Denali exceeded revenue expectations and continues to develop therapies for neurodegenerative diseases.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report

    Denali Therapeutics (DNLI) reported Q2 2026 revenue of US$3.6 million and a net loss of US$127.55 million. While the company's shares have shown strong recent momentum, trading at US$24.40, there are conflicting views on its valuation, with one narrative suggesting it's 41.9% undervalued at $42.00, while a DCF model indicates it's expensive at its current price. The company's valuation is heavily influenced by the performance of its AVLAYAH product and the pipeline risks.

    Sahm•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About DNLI

    Does DNLI pay dividends?
    Denali Therapeutics Inc (DNLI) does not currently pay a regular dividend.
    What is DNLI's market cap?
    Denali Therapeutics Inc (DNLI) has a market capitalization of $3.80B with a current stock price of $23.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In